Asset profile
Camrelizumab
Monoclonal antibody
Partialsignal
Evidence outlook · lead readout
NCT03134872 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic...
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT03134872: The study randomly assigned 419 participants to treatment or an active chemotherapy comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Featured evidence outside covered markets:NCT04613674 · Triple Negative Breast Cancer · Phase 3 · met primary endpoint · Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
83 competitors in this universe: 22 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 61 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Camrelizumab: this drug | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Nivolumab | Approved | Monoclonal antibody | PD-1 | ||
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab Berahyaluronidase Alfa | Approved | Monoclonal antibody | PD-1 | ||
| Retifanlimab | Approved | Monoclonal antibody | PD-1 | ||
| Toripalimab | Approved | Monoclonal antibody | PD-1 | ||
| Abp 234 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Balstilimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| CT-P51 | Phase 3 | Small molecule | PD-1 | ||
| Dostarlimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | ||
| MB12 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Penpulimab | Phase 3 | Monoclonal antibody | PD-1 |
…and 68 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Cemiplimab · Non-Small Cell Lung Cancervs Nivolumab · Non-Small Cell Lung Cancervs Pembrolizumab · Non-Small Cell Lung Cancervs Retifanlimab · Non-Small Cell Lung Cancervs Toripalimab · Non-Small Cell Lung Cancervs Dostarlimab · Non-Small Cell Lung Cancer
16 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(76 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (16)
October 2026 (1)
Phase 1/2Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic LymphomaRecruiting
Est. primary completion 2026-10-31 · NCT06376721 · CT.gov ↗
What to watch
November 2026 (2)
December 2026 (13)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07107217 · CT.gov ↗
What to watch
Phase 2/3Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT04208347 · CT.gov ↗
What to watch
Phase 2Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT07530094 · CT.gov ↗
What to watch
Phase 2Gestational Trophoblastic NeoplasiaRecruiting
Est. primary completion 2026-12-01 · NCT05139095 · CT.gov ↗
What to watch
Phase 2Cervical Cancer Metastatic, Cervical Cancer RecurrentNot yet recruiting
Est. primary completion 2026-12-30 · NCT07143292 · CT.gov ↗
What to watch
Phase 1Breast NeoplasmsRecruiting
Est. primary completion 2026-12-31 · NCT06121557 · CT.gov ↗
What to watch
Phase 1/2Breast Cancer, Triple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2026-12-31 · NCT07161791 · CT.gov ↗
What to watch
Phase 2Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal CancerRecruiting
Est. primary completion 2026-12-31 · NCT06831175 · CT.gov ↗
What to watch
Phase 2Hepatocellulcar CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07238881 · CT.gov ↗
What to watch
Phase 2Cervical Cancer, ImmunochemotherapyRecruiting
Est. primary completion 2026-12-31 · NCT07167160 · CT.gov ↗
What to watch
Phase 3Triple-negative Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06533384 · CT.gov ↗
What to watch
Early phase / not applicableEsophageal Squamous Cell Carcinoma (ESCC)Not yet recruiting
Est. primary completion 2026-12-31 · NCT07067450 · CT.gov ↗
What to watch
2027 (32)
January 2027 (2)
Phase 2Metastatic Pancreatic CarcinomaNot yet recruiting
Est. primary completion 2027-01-15 · NCT06759090 · CT.gov ↗
What to watch
Phase 2Unresectable Metastatic Rectal Cancer, CAPOX, Combination of RadioimmunotherapyNot yet recruiting
Est. primary completion 2027-01-30 · NCT07059949 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Advanced Esophageal CarcinomaNot yet recruiting
Est. primary completion 2027-02-01 · NCT06745193 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-03-31 · NCT06632405 · CT.gov ↗
What to watch
Phase 2Unresectable Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03-31 · NCT06360042 · CT.gov ↗
What to watch
Early phase / not applicableHCC - Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-03-31 · NCT07618546 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Germline BRCA-mutated HER2-negative Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05576389 · CT.gov ↗
What to watch
May 2027 (2)
Phase 3Advanced Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05-01 · NCT05738616 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint InhibitorsNot yet recruiting
Est. primary completion 2027-05-31 · NCT07159217 · CT.gov ↗
What to watch
June 2027 (2)
July 2027 (1)
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2027-07-01 · NCT05772273 · CT.gov ↗
What to watch
August 2027 (2)
September 2027 (2)
October 2027 (1)
Phase 3Rectal CancerRecruiting
Est. primary completion 2027-10-01 · NCT06229041 · CT.gov ↗
What to watch
November 2027 (2)
December 2027 (13)
Phase 2Esophageal Squamour Cell CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07191977 · CT.gov ↗
What to watch
Phase 2Endometrioid Endometrial CancerRecruiting
Est. primary completion 2027-12-01 · NCT06561308 · CT.gov ↗
What to watch
Phase 2Advanced Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06849492 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗
What to watch
Phase 2Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer AdultNot yet recruiting
Est. primary completion 2027-12-31 · NCT07314372 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-12-31 · NCT07154082 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07555860 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response, ChemotherapyRecruiting
Est. primary completion 2027-12-31 · NCT06811844 · CT.gov ↗
What to watch
Phase 2Unresectable Gallbladder CancerRecruiting
Est. primary completion 2027-12-31 · NCT06423170 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
2028 (16)
January 2028 (2)
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT06196671 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug RepurposingNot yet recruiting
Est. primary completion 2028-01-01 · NCT07324473 · CT.gov ↗
What to watch
February 2028 (2)
March 2028 (1)
Phase 2Breast Cancer Triple Negative Breast CancerActive not recruiting
Est. primary completion 2028-03-31 · NCT07471815 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2/3Metastatic Pancreatic CancerRecruiting
Est. primary completion 2028-05-31 · NCT06361888 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder CancerNot yet recruiting
Est. primary completion 2028-06-05 · NCT07639983 · CT.gov ↗
What to watch
July 2028 (3)
Phase 1/2Head and Neck CancerRecruiting
Est. primary completion 2028-07-01 · NCT07662681 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 3BCLC Stage C Hepatocellular Carcinoma, Chemotherapy EffectRecruiting
Est. primary completion 2028-07-31 · NCT06172205 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2/3Breast CancerRecruiting
Est. primary completion 2028-09-01 · NCT04803539 · CT.gov ↗
What to watch
December 2028 (5)
Phase 2Late-stage Resectable Esophageal Squamous CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07622797 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma, Neoadjuvant TherapyNot yet recruiting
Est. primary completion 2028-12-31 · NCT07505186 · CT.gov ↗
What to watch
Phase 3Breast Cancer Stage IV, Triple -Negative Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06889688 · CT.gov ↗
What to watch
Phase 3Resectable Esophageal Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-12-31 · NCT05043688 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2029-01-15 · NCT07328009 · CT.gov ↗
What to watch
February 2029 (2)
Phase 2Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity NeoplasmNot yet recruiting
Est. primary completion 2029-02 · NCT07400094 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal Cancer (CRC)Not yet recruiting
Est. primary completion 2029-02-01 · NCT07395063 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Hepato Cellular Carcinoma (HCC), Chemotherapy EffectRecruiting
Est. primary completion 2029-10 · NCT07267806 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Early phase / not applicableCervical Cancer, Radical Surgery, Adjuvant TherapyNot yet recruiting
Est. primary completion 2030-04-01 · NCT07466901 · CT.gov ↗
What to watch
2031 (2)
March 2031 (1)
Phase 2/3Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant ChemoimmunotherapyRecruiting
Est. primary completion 2031-03-01 · NCT06288373 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Rectal Cancer PatientsNot yet recruiting
Est. primary completion 2031-12-31 · NCT07521605 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Phase 1/2Breast NeoplasmsRecruiting
Est. primary completion 2032-04-30 · NCT05981001 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.